Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Hopkins

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Gynecologic Oncology|July 6, 2024
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancerPooja Praveen Kumar, DuPreez Smith, James Key, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian CancerKim Ma, Basile Tessier-Cloutier, Alon D Altman, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Gynecologic Oncology|July 6, 2024
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancerPooja Praveen Kumar, DuPreez Smith, James Key, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian CancerKim Ma, Basile Tessier-Cloutier, Alon D Altman, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Pageof 9